Home › RLT targets by cancer › Neuroendocrine Tumors
Radioligand therapy · Neuroendocrine Tumors

Radioligand Therapy Targets in Neuroendocrine Tumors

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in neuroendocrine tumors (including carcinoid and gastroenteropancreatic neuroendocrine tumors (GEP-NETs)). 3,969 show detectable protein staining. Established and emerging radioligand targets expressed in neuroendocrine tumors include HER3 (ERBB3), c-MET (MET), STEAP2 and SSTR2. Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Neuroendocrine tumors are the founding indication of peptide receptor radionuclide therapy (PRRT): SSTR2-targeted 177Lu-DOTATATE (Lutathera) is FDA-approved for GEP-NETs.

Need a shortlist for your own neuroendocrine tumors program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank neuroendocrine tumors targets free

Established and emerging radioligand targets in neuroendocrine tumors

Targets already pursued with radioligands or other targeted modalities that show protein expression in neuroendocrine tumors:

TargetIHC in neuroendocrine tumors% positiveInternalizes
HER3 (ERBB3)High (0.75)100%yes
c-MET (MET)High (0.58)100%yes
STEAP2High (0.58)100%—
SSTR2Medium (0.50)100%yes
EPCAMMedium (0.50)75%—
ITGB6Medium (0.42)100%—
ITGAVMedium (0.33)50%—
TMEFF2Medium (0.33)50%—
KITMedium (0.25)50%no
B7-H3 (CD276)Low (0.17)50%—
FAPLow (0.17)25%yes
Nectin-4 (NECTIN4)Low (0.08)25%no
CD19Low (0.08)25%—

Top cell-surface targets for neuroendocrine tumors radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in neuroendocrine tumors% positiveInternalizesClinical stage
1NR3C2
nuclear receptor subfamily 3 group C member 2
High (1.00)100%uncertainFDA-Approved
2IGF1R
insulin like growth factor 1 receptor
High (0.83)100%yesFDA-Approved
3HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.75)100%yesFDA-Approved
4CYSLTR2
cysteinyl leukotriene receptor 2
High (0.83)100%yesDiscovery
5AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
6c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.58)100%yesFDA-Approved
7SV2A
synaptic vesicle glycoprotein 2A
High (1.00)100%—FDA-Approved
8PTPN13
protein tyrosine phosphatase non-receptor type 13
High (0.92)100%yesDiscovery
9NOTCH3
notch receptor 3
High (0.75)100%yesClinical
10HTR6
5-hydroxytryptamine receptor 6
High (0.58)100%yesFDA-Approved
11PTPRB
protein tyrosine phosphatase receptor type B
High (0.67)67%yesClinical
12MAOB
monoamine oxidase B
High (0.92)100%—FDA-Approved
13HRH4
histamine receptor H4
High (0.75)100%yesClinical
14FLT4
fms related receptor tyrosine kinase 4
Medium (0.44)100%yesFDA-Approved
15FGFR1
fibroblast growth factor receptor 1
High (0.58)100%yesFDA-Approved
16ADRM1
ADRM1 26S proteasome ubiquitin receptor
High (0.92)100%uncertainFDA-Approved
17EPHB4
EPH receptor B4
High (0.58)100%yesFDA-Approved
18IL1R2
interleukin 1 receptor type 2
High (0.67)100%yesDiscovery
19FZD3
frizzled class receptor 3
High (0.83)100%yesDiscovery
20CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.67)100%yesClinical
21BDKRB1
bradykinin receptor B1
High (1.00)100%uncertainClinical
22EPHB2
EPH receptor B2
High (0.67)100%uncertainFDA-Approved
23ADGRL1
adhesion G protein-coupled receptor L1
High (0.83)100%yesDiscovery
24GPR139
G protein-coupled receptor 139
High (0.83)100%yesDiscovery
25IRAK4
interleukin 1 receptor associated kinase 4
High (0.67)100%yesClinical

Internalizing receptors in neuroendocrine tumors

Targets expressed in neuroendocrine tumors that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

IGF1R · HER3 (ERBB3) · CYSLTR2 · AMFR · c-MET (MET) · PTPN13 · NOTCH3 · HTR6 · PTPRB · HRH4 · FLT4 · FGFR1

Neuroendocrine Tumors targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in neuroendocrine tumors. Clinical precedent lowers development risk but usually means more competition:

NR3C2 · IGF1R · HER3 (ERBB3) · c-MET (MET) · SV2A · NOTCH3 · HTR6 · PTPRB · MAOB · HRH4 · FLT4 · FGFR1

How these neuroendocrine tumors targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in neuroendocrine tumors, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank neuroendocrine tumors targets against your own criteria: isotope, organ limits, novelty.

Run a free neuroendocrine tumors analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist neuroendocrine tumors targets for your program · 5 free analyses, no card Rank neuroendocrine tumors targets free